GlassScriptPhysician profile
Marvin D Spann
NPI 1407044399
$4,593.95
in general payments reported to CMS, 2019-2025
30 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $638 · 2021: $80.10 · 2022: $584 · 2023: $1,028 · 2024: $1,079 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800 · Travel and Lodging: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.49 |
| Travel and Lodging | $763.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,413.39 | 2019-2025 | Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps |
| Allergan, INC. | $478.43 | 2019-2022 | |
| Mentor Worldwide LLC | $316.99 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Sientra, INC. | $280.70 | 2019-2020 | |
| Genentech USA, INC. | $238.74 | 2019-2021 | |
| Lilly USA, LLC | $216.46 | 2023-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $180.48 | 2019-2025 | Absorica Ld, Winlevi, Odomzo |
| Smith+Nephew, INC. | $130.50 | 2022 | |
| Integra Lifesciences Corporation | $122.28 | 2020 | |
| Ucb, INC. | $115.20 | 2025 | Bimzelx |
| Leo Pharma INC. | $113.45 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $110.52 | 2021-2025 | Tremfya |
| Pfizer INC. | $109.28 | 2021-2023 | |
| Dermavant Sciences, INC. | $102.44 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $102.08 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $96.01 | 2022-2025 | Sotyktu |
| Amgen INC. | $80.97 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $76.69 | 2022-2024 | Dupixent |
| Tela Bio, INC. | $60.83 | 2022 | |
| Almirall LLC | $54.34 | 2019-2020 | |
| Incyte Corporation | $29.68 | 2025 | Opzelura |
| Galderma Laboratories, L.P. | $28.44 | 2025 | Nemluvio |
| Pacira Pharmaceuticals Incorporated | $26.77 | 2025 | Exparel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.38 | 2019-2020 | |
| Celgene Corporation | $23.07 | 2019 | |
| Journey Medical Corporation | $18.52 | 2019 | |
| Epi Health, LLC | $17.51 | 2019 | |
| Strata Skin Sciences, INC. | $11.81 | 2019 | |
| Organon LLC | $8.99 | 2025 | Vtama |
| Apyx Medical Corporation | $4.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Spann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.